Sign In
Buy IKNA
$1.43
+0 (+0%)
At Close: Oct 24, 2025
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
08:00am, Tuesday, 12'th Mar 2024
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dos
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
08:00am, Tuesday, 27'th Feb 2024
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
04:15pm, Wednesday, 21'st Feb 2024
Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
10:37am, Wednesday, 14'th Feb 2024
The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
10:36am, Wednesday, 24'th Jan 2024
Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
04:05pm, Thursday, 18'th Jan 2024
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core ta
Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptio
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
08:00am, Tuesday, 07'th Nov 2023
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today
NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Ikena Oncology Inc. (NASDAQ: IKNA) concerning possible breaches of fiduciary duty. To obta
Ikena Oncology to Participate in September 2023 Investor Conferences
08:00am, Tuesday, 05'th Sep 2023
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, toda
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates
10:46am, Thursday, 10'th Aug 2023
Ikena Oncology, Inc. (IKNA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.57 per share a year ago.
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
08:00am, Thursday, 10'th Aug 2023
Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by y
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
07:00am, Monday, 07'th Aug 2023
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif.,
Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
10:16am, Tuesday, 20'th Jun 2023
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why
09:53am, Friday, 02'nd Jun 2023
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
